Table 9.
Follow-up period 2 (POD 14 and discharge day)
| POD 14 | Discharge day | |
| Hb (g/L) | ||
| WBC (109/L) | ||
| PLT (109/L) | ||
| NEUT% | ||
| CRP (mg/L)* | ||
| PCT (ng/mL)* | ||
| PT (S) | ||
| INR | ||
| Fbg (g/L) | ||
| D-Dimer (mg/L)* | ||
| ALT (U/L) | ||
| AST (U/L) | ||
| Tbil (µmol/L) | ||
| LDH (U/L) | ||
| Crea (µmol/L) | ||
| ALB (g/L) | ||
| PA (mg/L) | ||
| ALP (U/L) | ||
| GGT (U/L) | ||
| Ammonia (mg/L)* | ||
| Collection of blood specimens | ||
| US* | ||
| Performance status (ECOG) | ||
| Quality of life (EQ-5D) | ||
| Complications | □0N□1Y | □0N□1Y |
| Adverse events | □0N□1Y | □0N□1Y |
| Medication records | □0N□1Y | □0N□1Y |
| Recipient survival status | □1N□1Y | □0N□1Y |
| Graft survival status | □0N□1Y | □0N□1Y |
Complications, adverse events and medication records are recorded in detail in the case report form.
*If necessary.
ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate transaminase; Crea, creatinine; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; EQ-5D, EuroQol-5 Dimension; Fbg, fibrinogen; GGT, glutamyl transpeptidase; Hb, haemoglobin; INR, international normalized ratio; LDH, lactate dehydrogenase; NEUT%, neutrophilic granulocyte percentage; PA, prealbumin; PCT, procalcitonin; PLT, platelets; PT, prothrombin time; Tbil, total bilirubin; US, ultrasound; WBC, white blood cells.